Works matching DE "MARAVIROC (Drug)"
Results: 186
Blocking CCR5.
- Published in:
- Nature Structural & Molecular Biology, 2013, v. 20, n. 10, p. 1145, doi. 10.1038/nsmb.2693
- By:
- Publication type:
- Article
Therapeutic use of CCR5 antagonists is supported by strong expression of CCR5 on CD8 T cells in progressive multifocal leukoencephalopathy-associated immune reconstitution inflammatory syndrome.
- Published in:
- 2015
- By:
- Publication type:
- Letter
High CCR5 expression in natalizumab-associated progressive multifocal leukoencephalopathy immune reconstitution inflammatory syndrome supports treatment with the CCR5 inhibitor maraviroc.
- Published in:
- 2015
- By:
- Publication type:
- Letter
Overview on Chemokine Co-Receptor-5 (CCR-5) HIV-1 Entry Inhibitors.
- Published in:
- Journal of Drug Delivery & Therapeutics, 2018, v. 8, n. 4, p. 73, doi. 10.22270/jddt.v8i4.1794
- By:
- Publication type:
- Article
Week 96 results of the randomized, multicentre Maraviroc Switch ( MARCH) study.
- Published in:
- HIV Medicine, 2018, v. 19, n. 1, p. 65, doi. 10.1111/hiv.12532
- By:
- Publication type:
- Article
Genotypic tropism testing of proviral DNA to guide maraviroc initiation in aviraemic subjects: 48-week analysis of results from the PROTEST study.
- Published in:
- HIV Medicine, 2017, v. 18, n. 7, p. 482, doi. 10.1111/hiv.12479
- By:
- Publication type:
- Article
Off-licence use of once-daily maraviroc in children and adolescents with perinatally acquired HIV-1 infection.
- Published in:
- HIV Medicine, 2017, v. 18, n. 4, p. 311, doi. 10.1111/hiv.12467
- By:
- Publication type:
- Article
Viral and inflammatory markers in cerebrospinal fluid of patients with HIV-1-associated neurocognitive impairment during antiretroviral treatment switch.
- Published in:
- HIV Medicine, 2015, v. 16, n. 6, p. 388, doi. 10.1111/hiv.12243
- By:
- Publication type:
- Article
Efficacy and safety of once-daily maraviroc plus ritonavir-boosted darunavir in pretreated HIV-infected patients in a real-life setting.
- Published in:
- HIV Medicine, 2014, v. 15, n. 7, p. 417, doi. 10.1111/hiv.12129
- By:
- Publication type:
- Article
Glioblastoma: synergy of growth promotion between CCL5 and NK-1R can be thwarted by blocking CCL5 with miraviroc, an FDA approved anti-HIV drug and blocking NK-1R with aprepitant, an FDA approved anti-nausea drug R. E. Kast Translational medicine.
- Published in:
- Journal of Clinical Pharmacy & Therapeutics, 2010, v. 35, n. 6, p. 657, doi. 10.1111/j.1365-2710.2009.01148.x
- By:
- Publication type:
- Article
In vitro effect of anti-human immunodeficiency virus CCR5 antagonist maraviroc on chemotactic activity of monocytes, macrophages and dendritic cells.
- Published in:
- Clinical & Experimental Immunology, 2011, v. 166, n. 2, p. 184, doi. 10.1111/j.1365-2249.2011.04409.x
- By:
- Publication type:
- Article
Decreased darunavir concentrations during once-daily co-administration with maraviroc and raltegravir: OPTIPRIM-ANRS 147 trial.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Serious neuropsychiatric adverse effects related to interaction between itraconazole and darunavir/ritonavir in an HIV-infected patient with cerebral histoplasmosis.
- Published in:
- 2018
- By:
- Publication type:
- journal article
V3-Loop genotypes do not predict maraviroc susceptibility of CCR5-tropic virus or clinical response through week 48 in HIV-1-infected, treatment-experienced persons receiving optimized background regimens.
- Published in:
- Antiviral Chemistry & Chemotherapy, 2021, p. 1, doi. 10.1177/20402066211030380
- By:
- Publication type:
- Article
Highly prevalent Russian HIV-1 V3-loop sequence variants are susceptible to maraviroc.
- Published in:
- Antiviral Chemistry & Chemotherapy, 2021, p. 1, doi. 10.1177/20402066211025156
- By:
- Publication type:
- Article
Mutations in variable domains of the HIV-1 envelope gene can have a significant impact on maraviroc and vicriviroc resistance.
- Published in:
- AIDS Research & Therapy, 2013, v. 10, p. 15, doi. 10.1186/1742-6405-10-15
- By:
- Publication type:
- Article
Effect of HIV-1 subtype and tropism on treatment with chemokine coreceptor entry inhibitors; overview of viral entry inhibition.
- Published in:
- Critical Reviews in Microbiology, 2015, v. 41, n. 4, p. 473, doi. 10.3109/1040841X.2013.867829
- By:
- Publication type:
- Article
Analysis of Physicochemical and Structural Properties Determining HIV-1 Coreceptor Usage.
- Published in:
- PLoS Computational Biology, 2013, v. 9, n. 3, p. 1, doi. 10.1371/journal.pcbi.1002977
- By:
- Publication type:
- Article
The Evolutionary Analysis of Emerging Low Frequency HIV-1 CXCR4 Using Variants through Time--An Ultra-Deep Approach.
- Published in:
- PLoS Computational Biology, 2010, v. 6, n. 12, p. 1, doi. 10.1371/journal.pcbi.1001022
- By:
- Publication type:
- Article
Decreased darunavir concentrations during once-daily co-administration with maraviroc and raltegravir: OPTIPRIM-ANRS 147 trial.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2018, v. 73, n. 4, p. 1020, doi. 10.1093/jac/dkx498
- By:
- Publication type:
- Article
Penetration and antiviral efficacy of total and unbound maraviroc, raltegravir and rilpivirine in both female and male genital fluids from HIV-positive patients receiving regimens containing these antiretrovirals.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Randomized controlled trial of the tolerability and completion of maraviroc compared with Kaletra® in combination with Truvada® for HIV post-exposure prophylaxis (MiPEP Trial).
- Published in:
- 2017
- By:
- Publication type:
- journal article
Maraviroc/raltegravir simplification strategy following 6 months of quadruple therapy with tenofovir/emtricitabine/maraviroc/raltegravir in treatment-naive HIV patients.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Factors associated with virological response to a switch regimen containing maraviroc for antiretroviral-experienced HIV-1-infected patients.
- Published in:
- 2016
- By:
- Publication type:
- journal article
A randomized clinical trial comparing ritonavir-boosted lopinavir versus maraviroc each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Virological factors associated with outcome of dual maraviroc/raltegravir therapy (ANRS-157 trial).
- Published in:
- 2015
- By:
- Publication type:
- journal article
Lack of a significant pharmacokinetic interaction between maraviroc and tacrolimus in allogeneic HSCT recipients.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2015, v. 70, n. 7, p. 2078, doi. 10.1093/jac/dkv082
- By:
- Publication type:
- Article
Virological failure of patients on maraviroc-based antiretroviral therapy.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2015, v. 70, n. 6, p. 1858, doi. 10.1093/jac/dkv026
- By:
- Publication type:
- Article
Costo-efectividad de maraviroc más tratamiento de base optimizado en pacientes con VIH/SIDA.
- Published in:
- Medicina Interna de Mexico, 2010, v. 26, n. 3, p. 199
- By:
- Publication type:
- Article
A Validated Stability-Indicating UPLC Method for the Determination of Impurities in Maraviroc.
- Published in:
- Journal of Chromatographic Science, 2014, v. 52, n. 7, p. 609, doi. 10.1093/chromsci/bmt085
- By:
- Publication type:
- Article
Interactions between Alcohol and the HIV Entry Inhibitor Maraviroc.
- Published in:
- Journal of the International Association of Providers of AIDS Care, 2013, v. 12, n. 6, p. 375, doi. 10.1177/2325957413495567
- By:
- Publication type:
- Article
The effect of maraviroc on the pharmacokinetics of digoxin in healthy volunteers.
- Published in:
- Clinical Pharmacology in Drug Development, 2014, v. 3, n. 3, p. 202, doi. 10.1002/cpdd.91
- By:
- Publication type:
- Article
Two-Drug Treatment Approaches in HIV: Finally Getting Somewhere?
- Published in:
- Drugs, 2016, v. 76, n. 5, p. 523, doi. 10.1007/s40265-016-0553-8
- By:
- Publication type:
- Article
No Clinical Impact of CYP3A5 Gene Polymorphisms on the Pharmacokinetics and/or Efficacy of Maraviroc in Healthy Volunteers and HIV‐1–Infected Subjects.
- Published in:
- Journal of Clinical Pharmacology, 2019, v. 59, n. 1, p. 139, doi. 10.1002/jcph.1306
- By:
- Publication type:
- Article
Clinical Pharmacology Profile of Raltegravir, an HIV-1 Integrase Strand Transfer Inhibitor.
- Published in:
- Journal of Clinical Pharmacology, 2011, v. 51, n. 10, p. 1376, doi. 10.1177/0091270010387428
- By:
- Publication type:
- Article
A comparison of two post-processing analysis methods to quantify cerebral metabolites measured via proton magnetic resonance spectroscopy in HIV disease.
- Published in:
- British Journal of Radiology, 2016, v. 89, n. 1060, p. 1, doi. 10.1259/bjr.20150979
- By:
- Publication type:
- Article
Impaired Maraviroc and Raltegravir Clearance in a Human Immunodeficiency Virus-Infected Patient with End-Stage Liver Disease and Renal Impairment: A Management Dilemma.
- Published in:
- Pharmacotherapy, 2012, v. 32, n. 1, p. e1, doi. 10.1002/PHAR.1003
- By:
- Publication type:
- Article
Abstracts ICAR 2010.
- Published in:
- Infection, 2010, v. 38, p. 1, doi. 10.1007/s15010-010-1001-4
- Publication type:
- Article
INTENSIFIED TREATMENT QUICKLY REDUCES LOW-LEVEL VIRAL SHEDDING IN SEMEN.
- Published in:
- HIV Australia, 2013, v. 11, n. 1, p. 50
- Publication type:
- Article
The CCL5/CCR5 Axis in Cancer Progression.
- Published in:
- Cancers, 2020, v. 12, n. 7, p. 1765, doi. 10.3390/cancers12071765
- By:
- Publication type:
- Article
The effects of Maraviroc on liver fibrosis in HIV/HCV co-infected patients.
- Published in:
- Journal of the International AIDS Society, 2014, v. 17, p. n/a, doi. 10.7448/IAS.17.4.19643
- By:
- Publication type:
- Article
Use of maraviroc in patients with undetectable viral load: efficacy, tolerance and predictors of viral response in MARAVIROC-cohort study.
- Published in:
- Journal of the International AIDS Society, 2014, v. 17, p. n/a, doi. 10.7448/IAS.17.4.19800
- By:
- Publication type:
- Article
First prospective comparison of genotypic vs phenotypic tropism assays in predicting virologic responses to Maraviroc (MVC) in a phase 3 study: MODERN.
- Published in:
- Journal of the International AIDS Society, 2014, v. 17, p. n/a, doi. 10.7448/IAS.17.4.19519
- By:
- Publication type:
- Article
Treatment outcome in HIV+ patients receiving 3- or 4-drug regimens during PHI.
- Published in:
- Journal of the International AIDS Society, 2014, v. 17, p. n/a, doi. 10.7448/IAS.17.4.19778
- By:
- Publication type:
- Article
Cenicriviroc blocks HIV entry but does not lead to redistribution of HIV into extracellular space like maraviroc.
- Published in:
- Journal of the International AIDS Society, 2014, v. 17, p. n/a, doi. 10.7448/IAS.17.4.19531
- By:
- Publication type:
- Article
Improvement of endothelial function after switching previously treated HIV-infected patients to an NRTI-sparing bitherapy with maraviroc.
- Published in:
- Journal of the International AIDS Society, 2014, v. 17, p. n/a, doi. 10.7448/IAS.17.4.19726
- By:
- Publication type:
- Article
Bone mineral density improvement after 48 weeks of switch to maraviroc+darunavir/ritonavir 300/800/100 mg QD, preliminary results of GUSTA study.
- Published in:
- Journal of the International AIDS Society, 2014, v. 17, p. n/a, doi. 10.7448/IAS.17.4.19816
- By:
- Publication type:
- Article
Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study.
- Published in:
- Journal of the International AIDS Society, 2014, v. 17, p. n/a, doi. 10.7448/IAS.17.4.19818
- By:
- Publication type:
- Article
Effectiveness, safety, durability and immune recovery in a retrospective, multicentre, observational cohort of ART-experienced, HIV-1-infected patients receiving maraviroc.
- Published in:
- 2017
- By:
- Publication type:
- journal article
The utility of genotypic tropism testing in clinical practice.
- Published in:
- International Journal of STD & AIDS, 2015, v. 26, n. 8, p. 593, doi. 10.1177/0956462414546917
- By:
- Publication type:
- Article